Table 2:
Retention in care and PrEP adherence based on tenofovir drug concentrations by study group
| Outcome | Time point | n * | Intervention | Control | Unadjusted probability difference (95% CI) | Adjusted probability difference (95% CI)^ |
|---|---|---|---|---|---|---|
| Retained in care | ||||||
| At Month 3 | 200 | 90/100 (90.0%) | 89/100 (89.0%) | 1.0% (−7.5%, 9.5%) | 5.1% (−3.7%, 14.0%) | |
| At Month 6 | 200 | 88/100 (88.0%) | 83/100 (83.0%) | 5.0% (−4.7%, 14.7%) | 7.4% (−2.7%, 17.4%) | |
| Functional PrEP levels among women retained in care (score of 4 or 5) | ||||||
| At Month 3 | 178 | 28/89 (31.5%) | 29/89 (32.6%) | −1.1% (−14.8%, 12.6%) | −4.5% (−20.0%, 11.0%) | |
| At Month 6 | 170 | 22/88 (25.0%) | 26/82 (31.7%) | −6.7% (−20.3%, 6.8%) | −9.7% (−34.4%, 4.9%) | |
| Retained in care with functional PrEP levels (score of 4 or 5) | ||||||
| At Month 3 | 199 | 28/99 (28.3%) | 29/100 (29.0%) | −0.7% (−13.3%, 11.8%) | −1.8% (−16.2%, 12.7%) | |
| At Month 6 | 199 | 22/100 (22.0%) | 26/99 (26.3%) | −4.3% (−16.1%, 7.6%) | −5.5% (−18.0%, 6.9%) | |
*
One specimen misplaced at Month 3 and one specimen misplaced at Month 6; outcomes set to missing
^
Model adjusted for baseline imbalances in gestational age (continuous, in weeks), socioeconomic status (measured as presence of electricity in the home), financial dependence on partner (yes vs. no), number of lifetime sexual partners (continuous), intercourse frequency in the 30 days prior to enrollment (continuous), and perceived HIV risk at enrollment (no or low risk vs. moderate or high risk)